CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Tools and Technologies I |
The Stem Cell Matrix: a map of the molecular pathways that define pluripotent cells |
$1,133,552 |
| Scripps Research Institute |
Dr. Carlos F. Barbas Dr. |
Tools and Technologies I |
Development of a novel technology for precise, efficient, and safe genetic modification of stem cells |
$1,138,548 |
| University of California, Santa Cruz |
Dr. Joel Alan Kubby |
Tools and Technologies I |
AO Wide-Field Microscope |
$549,551 |
| University of California, San Diego |
Dr. Steven F Dowdy |
Tools and Technologies I |
TAT Cell-Permeable Protein Delivery of siRNAs for Epigenetic Programming of Human Pluripotent and Adult Stem Cells |
$720,000 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg |
Tools and Technologies I |
Synthetic Matrices for Stem Cell Growth and Differentiation |
$599,404 |
| Fluidigm Corporation |
Dr. Marc A Unger |
Tools and Technologies I |
Scaleup of Versatile, Fully Automated, Microfluidic Cell Culture System |
$749,518 |
| University of California, Los Angeles |
Dr. Hsian-Rong Tseng |
Tools and Technologies I |
Microfluidic Platform for Screening Chemically Defined Conditions that Facilitate Clonal Expansion of Human Pluripotent Stem Cells |
$914,096 |
| VistaGen Therapeutics, Inc. |
Dr. Kristina Bonham |
Tools and Technologies I |
Development of an hES Cell-Based Assay System for Hepatocyte Differentiation Studies and Predictive Toxicology Drug Screening |
$971,558 |
| University of California, Berkeley |
John Dueber |
Tools and Technologies I |
Directed Evolution of Novel AAV Variants for Enhanced Gene Targeting in Pluripotent Human Stem Cells and Investigation of Dopaminergic Neuron Differentiation |
$918,000 |
| University of Southern California |
Dr. Martin Pera |
Shared Labs |
USC Center for Stem Cell and Regenerative Medicine: Shared Research Laboratory and Course in Current Protocols in Human Embryonic Stem Cell Research |
$1,724,015 |
| University of California, San Francisco |
Dr. Linda C. Giudice |
Shared Labs |
The University of California San Francisco Shared Research and Teaching Laboratory: a Non-Federal Human Embryonic Stem Cell Resource for the Bay Area Community |
$2,144,758 |
| University of California, San Diego |
Karl H. Willert |
Shared Labs |
Enhancing Facilities for Genetic Manipulation and Engineering of Human Embryonic Stem Cells at UCSD |
$1,728,080 |
| University of California, Santa Barbara |
Prof Dennis O Clegg |
Shared Labs |
The UCSB Laboratory for Stem Cell Biology and Engineering |
$1,407,192 |
| University of California, Irvine |
Dr. Peter J Donovan |
Shared Labs |
The University of California: Irvine Regional Human Embryonic Stem Cell Shared Research Laboratory and Stem Cell Techniques Course |
$2,107,376 |
| University of California, Berkeley |
John Dueber |
Shared Labs |
The Berkeley Human Embryonic Stem Cell Shared Research Laboratory |
$1,227,659 |
| Stanford University |
Renee Reijo Pera |
Shared Labs |
The Stanford University Center for Human Embryonic Stem Cell Research and Education |
$2,439,590 |
| Gladstone Institutes, J. David |
Dr. Deepak Srivastava |
Shared Labs |
The Gladstone CIRM Shared Human Embryonic Stem Cell Core Laboratory |
$842,672 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Jeanne F Loring |
Shared Labs |
Collaborative Laboratory for Human Embryonic Stem Cell Research at Sanford-Burnham Medical Research Institute |
$1,361,825 |
| The Regents of the University of California on behalf of its Riverside Campus |
Dr. Prue Talbot |
Shared Labs |
A Stem Cell Core Facility for Studying Human Embryonic Stem Cell Differentiation |
$1,976,931 |
| Children’s Hospital of Los Angeles |
Carolyn Lutzko |
Shared Labs |
The Childrens Hospital of Los Angeles hESC Facility |
$1,684,648 |
| University of California, Santa Cruz |
Dr. Lindsay Hinck |
Shared Labs |
UCSC Shared Stem Cell Facility |
$1,849,452 |
| University of California, Los Angeles |
Scott Waugh |
Shared Labs |
CIRM Shared Research Laboratories |
$2,000,000 |
| University of California, Davis |
Dr. Alice F Tarantal |
Shared Labs |
UC Davis Translational Human Embryonic Stem Cell Shared Research Facility |
$2,000,000 |
| Scripps Research Institute |
Sheng Ding PhD |
Shared Labs |
TSRI Center for hESC Research |
$1,440,164 |
| Buck Institute for Age Research |
Dr. Xianmin Zeng |
Shared Labs |
North Bay CIRM Shared Research Laboratory for Stem Cells and Aging |
$2,414,749 |
| Salk Institute for Biological Studies |
Garry Van Gerpen |
Shared Labs |
Shared viral vector facility for genetic manipulation of huamn ES cell |
$1,478,923 |
| University of California, San Francisco |
Dr. Linda C. Giudice |
Shared Labs |
The University of California San Francisco Shared Research and Teaching Laboratory: a Non-Federal Human Embryonic Stem Cell Resource for the Bay Area Community |
$3,289,649 |
| University of California, San Diego |
Karl H. Willert |
Shared Labs |
Enhancing Facilities for Genetic Manipulation and Engineering of Human Embryonic Stem Cells at UCSD |
$1,737,133 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg |
Shared Labs |
The UCSB Laboratory for Stem Cell Biology and Engineering |
$1,638,357 |
| Stanford University |
Prof Vittorio Sebastiano |
Shared Labs |
The Stanford University Center for Human Embryonic Stem Cell Research and Education |
$3,434,600 |
| Gladstone Institutes, J. David |
Dr. Deepak Srivastava |
Shared Labs |
The Gladstone CIRM Shared Human Embryonic Stem Cell Core Laboratory |
$1,698,515 |
| The Regents of the University of California on behalf of its Riverside Campus |
Dr. Prue Talbot |
Shared Labs |
A Stem Cell Core Facility for Studying Human Embryonic Stem Cell Differentiation |
$1,663,284 |
| University of California, Los Angeles |
Dr. Owen N Witte M.D. |
Shared Labs |
CIRM Shared Research Laboratories |
$1,751,297 |
| University of California, Davis |
Dr. Alice F Tarantal |
Shared Labs |
UC Davis Translational Human Embryonic Stem Cell Shared Research Facility |
$1,728,111 |
| Children’s Hospital of Los Angeles |
Dr. David Warburton |
Shared Labs |
The Childrens Hospital of Los Angeles hESC Facility |
$1,750,259 |
| University of California, Santa Cruz |
Dr. Lindsay Hinck |
Shared Labs |
UCSC Shared Stem Cell Facility |
$1,719,722 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Shared Labs |
TSRI Center for hESC Research |
$3,725,070 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Sara Collins |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |
| Loma Linda University |
Hisham Abdel-Azim |
CCCE Grant |
Inland Empire and Desert Region CIRM Community Care Center of Excellence |
$9,000,000 |
